Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
I've noted with interest disturbances in NPI crisis management, broadcast sotto voce by the press corpse. These are, incremental shifts in emphasis from eradicating The One pathogen (beside CHINA) threatening civilization to a process of attenuating myriad active, "off-label" ingredients used to treat "moderate and severe" double "pneumonia-like" symptoms to "promising," authorized, brand-name experimental immuno-modulating products that induce synthetic SARS-CoV-2 or bacterial antigens, rather than repair COVID-19 injuries and rehabilitate ADLs.

Omicron may sideline two leading drugs against COVID-19

For more than a year antibody drugs from Regeneron and Eli Lilly have been the go-to treatments for early COVID-19, thanks to their ability to head off severe disease and keep patients out of the hospital.
A third antibody from British drugmaker GlaxoSmithKline appears to be the best positioned to fight omicron. But Glaxo's drug is not widely available in the U.S., accounting for a small portion of the millions of doses purchased and distributed by the federal government. U.S. health officials are now rationing scarce drug supplies to states.

For the past 2 years, government PR communicated the singular measure of morbidity as presentation of the disease, COVID-19. Obversely, daily estimates of partial and full dosage, or aggregate uptake, of an extremely limited set of antiviral medication d/b/a SARS-CoV-2 vaccines have satisfied popular expectations of "herd immunity" derived from institutional compliance despite statistically insignificant reductions in rates SARS-CoV-2 mutations, variants' "transmissibility," and death attributed either to grave dangers of non-compliance alone. "Vulnerability" masks "pre-existing conditions," excluding contraindicated pharmacology. Never serial infection ("breakthrough vaccine" cases). Never clinical incompetence.

NEVERTHELESS, observations such as supply chain failures (Q attenuated test devices, Q clinical personnel, Big Data std deviations, val + vol mRNA inventory, R&D, useful life), and authoritative controversies (political and clinical) continue to confound the predictive power of pharmaceutical agents (political and chemical) and furnish much larger markets populated by the living, ("long" or "recovered") COVID-19 "consumer-patients," already captured by multiple maintenance drug regimen "pharmacokinetics".

In Clinical Care, What Will Amazon Deliver?

Public education in healthcare offered by paid "social media" has well and truly undermined the credibility of industrial medicine as advertised, while contributing to GDP dominated by self-service economies of scale.
archived single point of pharma mRNA engineered FAILURE, Fri Nov 5th, 2021, Wed Sep 8th, 2021

by Cat on Sun Dec 19th, 2021 at 08:59:00 PM EST

Others have rated this comment as follows:

Oui 4


Occasional Series